Alnylam Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030

Updated on 05/27/2023

Stock Rating
7
Price Target
$251.00
Consensus
Outperform
Upside
33.33%
Analysts
7
Stock Rating
7
Upside
33.33%
Analysts
7
Price Target
$251.00

Alnylam Pharmaceuticals Inc Stock Forecast and Price Target

In recent months, seven notable analysts have provided yearlong price targets for Alnylam Pharmaceuticals Inc, with the average target coming in at $251.00. If it were to be achieved, this would result in a potential upside of approximately 33.33 percent from the most recent closing price in May, 2023. The high end is $415.00, and the low is $143.00. Although you may not be interested in ALNY stock, you should still be aware of its competitors.

$251.00

33.33% Upside

Outperform
Outperform

Alnylam Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals Inc's Price has grown from $0.00 to $0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach $200.74 – an increase of 100.00%. Over the next eight years, the forecast is for Fair Value to grow by 100.00%.

2023 Fair Value Forecast
$200.74
2024 Fair Value Forecast
$223.21
2025 Fair Value Forecast
$248.18
2026 Fair Value Forecast
$275.95
2027 Fair Value Forecast
$306.83
2028 Fair Value Forecast
$341.17
2029 Fair Value Forecast
$379.35
2030 Fair Value Forecast
$421.79
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 10
$154.35 Buy/Sell $178.79 16.94%
LLY Stock Forecast Eli Lilly & Co Outperform 14
$425.79 Buy/Sell $333.19 -6.06%
PFE Stock Forecast Pfizer Inc Outperform 3
$37.60 Buy/Sell $47.96 40.03%
MRK Stock Forecast Merck Outperform 5
$111.07 Buy/Sell $99.57 6.24%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$63.82 Buy/Sell $80.99 30.05%

Alnylam Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030

In the last four years, Alnylam Pharmaceuticals Inc's Revenue has grown from $219.75M to $1.04B – a 372.09% increase. Next year, analysts are expecting Revenue to reach $1.47B – an increase of 41.43%. Over the next eight years, the forecast is for Revenue to grow by 833.22%.

2023 Rev Forecast
$1.47B
2024 Rev Forecast
$2.16B
2025 Rev Forecast
$2.80B
2026 Rev Forecast
$3.82B
2027 Rev Forecast
$5.27B
2028 Rev Forecast
$6.53B
2029 Rev Forecast
$8.30B
2030 Rev Forecast
$9.68B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$725.05 Buy/Sell $796.73 7.85%
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 13
$329.99 Buy/Sell $363.29 -1.21%
ZTS Stock Forecast Zoetis Outperform 18
$164.74 Buy/Sell $209.70 24.44%

Alnylam Pharmaceuticals Inc Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAX Stock Forecast Baxter International Inc Outperform 17
$41.29 Buy/Sell $60.73 40.47%
VTRS Stock Forecast Viatris Outperform 8
$9.11 Buy/Sell $13.70 48.19%
UTHR Stock Forecast United Therapeutics Outperform 12
$207.32 Buy/Sell $280.69 42.29%

Alnylam Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last four years, Alnylam Pharmaceuticals Inc's Free Cash Flow has grown, rising from $-418.59M to $-779.38T – a growth of 186192355.62%. In the following year, the 8 analysts surveyed believe that Alnylam Pharmaceuticals Inc's Free Cash Flow will decrease by 100.00%, reaching $-420.13M. According to professionals, by 2030, Alnylam Pharmaceuticals Inc's Free Cash Flow will have decreased by 100.00%, falling down to $3.40B.

2023 FCF Forecast
$-420130000.00
2024 FCF Forecast
$0.06B
2025 FCF Forecast
$0.46B
2026 FCF Forecast
$0.98B
2027 FCF Forecast
$1.78B
2028 FCF Forecast
$2.44B
2029 FCF Forecast
$3.55B
2030 FCF Forecast
$3.40B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CTLT Stock Forecast Catalent Outperform 15
$37.12 Buy/Sell $83.92 96.66%
IONS Stock Forecast Ionis Pharmaceuticals Outperform 9
$40.74 Buy/Sell $52.42 22.73%
CYTK Stock Forecast Cytokinetics Outperform 10
$37.36 Buy/Sell $62.67 60.60%

Alnylam Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030

In the last four years, Alnylam Pharmaceuticals Inc's Net Income has grown by 27.65%, rising from $-886.12M to $-1.13B. For the following year, the 12 analysts predict that Alnylam Pharmaceuticals Inc's Net Income will drop by 53.02%, reaching $-531.38M. In 2030, the professionals' prediction is that ALNY's Net Income will decrease by 467.74%, reaching $4.16B.

2023 NI Forecast
$-531380000.00
2024 NI Forecast
$0.12B
2025 NI Forecast
$0.63B
2026 NI Forecast
$1.23B
2027 NI Forecast
$2.33B
2028 NI Forecast
$2.84B
2029 NI Forecast
$3.73B
2030 NI Forecast
$4.16B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$122.51 Buy/Sell $163.67 33.87%
NEOG Stock Forecast Neogen Hold 16
$17.11 Buy/Sell $37.00 49.04%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$23.98 Buy/Sell $0.00 23.02%

Alnylam Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030

In the last four years, Alnylam Pharmaceuticals Inc's EBITDA has decreased from $-922.26M to $-894.44M – a 3.02% drop! The next year, 8 experts forecast that Alnylam Pharmaceuticals Inc's EBITDA will decrease by 37.20%, reaching $-561.69M. In 2030, professionals predict that Alnylam Pharmaceuticals Inc's EBITDA will decrease by 584.60%, reaching $4.33B.

2023 EBITDA Forecast
$-561690000.00
2024 EBITDA Forecast
$0.15B
2025 EBITDA Forecast
$0.46B
2026 EBITDA Forecast
$1.63B
2027 EBITDA Forecast
$3.42B
2028 EBITDA Forecast
$1.78B
2029 EBITDA Forecast
$2.87B
2030 EBITDA Forecast
$4.33B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
TGTX Stock Forecast TG Therapeutics Outperform 9
$27.20 Buy/Sell $73.38 -30.15%
INDV Stock Forecast Indivior PLC Buy 14
£170.50 Buy/Sell £3.79 -97.22%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$39.46 Buy/Sell $79.67 97.67%

Alnylam Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals Inc has seen a decline in its EBIT, from $-939.43M to $-708.65M – a 24.57% decrease. In the next year, analysts believe that EBIT will reach $-745.30M – an increase of 5.17%. By 2030, professionals believe that Alnylam Pharmaceuticals Inc's EBIT will have decreased by 866.53%, falling to $5.43B.

2023 EBIT Forecast
$-745300000.00
2024 EBIT Forecast
$-447340000.00
2025 EBIT Forecast
$-6970000.00
2026 EBIT Forecast
$0.34B
2027 EBIT Forecast
$0.93B
2028 EBIT Forecast
$2.76B
2029 EBIT Forecast
$4.30B
2030 EBIT Forecast
$5.43B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$44.14 Buy/Sell $41.00 -0.32%
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$10.81 Buy/Sell $12.60 15.63%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$33.62 Buy/Sell $35.50 1.13%

Alnylam Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals Inc's EPS has decreased from $-6.70 to $-6.14 – a 8.36% drop. Next year, analysts are expecting EPS to reach $-6.56 – an increase of 6.84%. In 2030, professionals predict that Alnylam Pharmaceuticals Inc's EPS will decrease by 540.72%, to $27.06.

2023 EPS Forecast
$-6.56
2024 EPS Forecast
$-3.26
2025 EPS Forecast
$0.11
2026 EPS Forecast
$3.94
2027 EPS Forecast
$9.46
2028 EPS Forecast
$17.16
2029 EPS Forecast
$23.45
2030 EPS Forecast
$27.06
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LGND Stock Forecast Ligand Pharmaceuticals Outperform 14
$72.13 Buy/Sell $195.43 119.74%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$284.88 Buy/Sell $170.08 -38.57%
USNA Stock Forecast USANA Health Sciences Hold 14
$62.77 Buy/Sell $104.00 -9.19%